These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 32952)

  • 21. Effects of nigral stimulation on locomotion and postural stability in patients with Parkinson's disease.
    Chastan N; Westby GW; Yelnik J; Bardinet E; Do MC; Agid Y; Welter ML
    Brain; 2009 Jan; 132(Pt 1):172-84. PubMed ID: 19001482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Etiology and physiopathology of patients with parkinson's disease].
    Ogawa N
    Nihon Naika Gakkai Zasshi; 2003 Aug; 92(8):1394-9. PubMed ID: 13677885
    [No Abstract]   [Full Text] [Related]  

  • 23. No evidence for altered muscle mitochondrial function in Parkinson's disease.
    Anderson JJ; Bravi D; Ferrari R; Davis TL; Baronti F; Chase TN; Dagani F
    J Neurol Neurosurg Psychiatry; 1993 May; 56(5):477-80. PubMed ID: 8505638
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.
    Whone AL; Watts RL; Stoessl AJ; Davis M; Reske S; Nahmias C; Lang AE; Rascol O; Ribeiro MJ; Remy P; Poewe WH; Hauser RA; Brooks DJ;
    Ann Neurol; 2003 Jul; 54(1):93-101. PubMed ID: 12838524
    [TBL] [Abstract][Full Text] [Related]  

  • 25. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
    Lindgren HS; Andersson DR; Lagerkvist S; Nissbrandt H; Cenci MA
    J Neurochem; 2010 Mar; 112(6):1465-76. PubMed ID: 20050978
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synaptic plasticity, dopamine and Parkinson's disease: one step ahead.
    Calabresi P; Mercuri NB; Di Filippo M
    Brain; 2009 Feb; 132(Pt 2):285-7. PubMed ID: 19168452
    [No Abstract]   [Full Text] [Related]  

  • 27. [Are dopamine agonists alternative therapy for levodopa in early stage of Parkinson's disease? No].
    Friedman A
    Neurol Neurochir Pol; 2007; 41(2 Suppl 1):S10-3. PubMed ID: 17941453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Search for the cause of Parkinson's disease].
    Langston JW
    Arch Neurobiol (Madr); 1991; 54(6):264-71. PubMed ID: 1811457
    [No Abstract]   [Full Text] [Related]  

  • 29. Cerebral atrophy and long-term response to levodopa in Parkinson's disease.
    Schneider E; Fischer PA; Jacobi P; Becker H; Beyer M
    J Neurol; 1979; 222(1):37-43. PubMed ID: 93625
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Senile Parkinsonism: its motor and psychological defects].
    Birkmayer W
    Aktuelle Gerontol; 1982 Sep; 12(5):166-7. PubMed ID: 6128932
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Problems and future perspectives in the treatment of Parkinson's disease].
    Hens L; Hellemans J
    Tijdschr Gerontol Geriatr; 1982 Aug; 13(4):147-54. PubMed ID: 6127822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Parkinson's disease.
    Wolters EC; Calne DB
    CMAJ; 1989 Mar; 140(5):507-14. PubMed ID: 2563667
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Developments in understanding the physiology and pharmacology of parkinsonism.
    Teräväinen H; Calne DB
    Acta Neurol Scand; 1979 Jul; 60(1):1-11. PubMed ID: 40381
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Drug therapy of parkinsonism].
    Teräväinen H; Larsen TA
    Duodecim; 1982; 98(11):892-900. PubMed ID: 6125373
    [No Abstract]   [Full Text] [Related]  

  • 35. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.
    Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ
    Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr.
    Lees AJ; Tolosa E; Olanow CW
    Mov Disord; 2015 Jan; 30(1):19-36. PubMed ID: 25488030
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Levodopa/dopamine replacement strategies in Parkinson's disease--future directions.
    Olanow CW
    Mov Disord; 2008; 23 Suppl 3():S613-22. PubMed ID: 18781663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Parkinson's disease: neuro-anatomical, biochemical and pharmicotherapeutic aspects].
    Korf J; van Praagen HM; Lakke JP
    Ned Tijdschr Geneeskd; 1975 Sep; 119(36):1373-8. PubMed ID: 241026
    [No Abstract]   [Full Text] [Related]  

  • 39. Actions of levodopa and dopamine in the central nervous system.
    Sourkes TL
    JAMA; 1971 Dec; 218(13):1909-11. PubMed ID: 4398939
    [No Abstract]   [Full Text] [Related]  

  • 40. A current analysis of behavioral problems in patients with idiopathic Parkinson's disease.
    Mayeux R
    Mov Disord; 1989; 4 Suppl 1():S48-56. PubMed ID: 2566913
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.